2023 Press Releases

11/16/2023

NASHVILLE, Tenn., Aachen, Germany, NOVEMBER 16, 2023 – BehaVR, a pioneering force in digital therapeutics (DTx) experiences, and Fern Health, a virtual chronic pain management program, today announced the signing of an agreement to merge their businesses and create a new digital care management solution for chronic pain.

8/2/2023

Aachen, Germany and Tokyo, Japan, 2 August 2023 – Grünenthal GmbH (CEO: Gabriel Baertschi), a global, science-based, privately-owned pharmaceutical company and Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the successful completion of a deal to enter into a Joint Venture Collaboration for Kyowa Kirin International's established medicines portfolio.

6/26/2023

Brussels/Aachen. 26 June 2023. The European Pain Federation EFIC^® and the pharmaceutical company Grünenthal have announced the three recipients of the EFIC-Grünenthal Grant (E-G-G). With a total value of €100,000, this biennial grant rewards innovative projects for human pain research and supports promising early-career researchers.

5/22/2023

Aachen, Germany, 22 May 2023 – Grünenthal today announced that its investigational non-opioid medicine resiniferatoxin (RTX), currently undergoing clinical Phase III development, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for pain associated with osteoarthritis (OA) of the knee. The decision is based on clinical phase I and II data indicating significant pain relief and a favourable safety profile.

4/27/2023

Aachen, Germany and London, England, 27 April 2023 – Grünenthal and King’s College London announced a 24 months collaboration to develop microfluidic culture (MFC) models based on human induced pluripotent stem cells (iPSCs) and tailored to pain research.

4/25/2023

Aachen, Germany, 25 April 2023 – Grünenthal GmbH (the “Company”) today announced that it has successfully placed its €300 million aggregate principal amount of 6.75% senior secured notes due 2030 (the “Notes”).

4/19/2023

Aachen, Germany, 19 April 2023 – Grünenthal GmbH (the “Company”) today announced the pricing of €300 million aggregate principal amount of 6.75% senior secured notes due 2030 (the “Notes”). The Notes will be issued at 100%. The Notes were offered outside the United States in reliance on Regulation S under the Securities Act of 1933, as amended (the “Securities Act”). In the United States, the Notes were offered only to qualified institutional buyers pursuant to Rule 144A under the Securities Act.

3/27/2023

Aachen, Germany, 27 March 2023 – Grünenthal, the leading pharmaceutical company in pain research and management, released its 2022 full-year results, announcing record revenue and adjusted EBITDA.

3/15/2023

SOMERSET, N.J., and AACHEN, Germany – March 15, 2023 – Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, and Grünenthal, an international science-driven pharmaceutical company and a global leader in pain research and management, today announced their successful formulation design and clinical-phase manufacturing collaboration for an orally dosed small molecule in Grünenthal's pipeline.

3/1/2023

Aachen, Germany, 1^st March 2023 – Janneke van der Kamp has today assumed her role as the new Chief Commercial Officer (CCO) of Grünenthal. She joins Grünenthal’s executive board and is responsible for the entire Global Commercial Organisation.